To read the full story, subscribe or sign in.

Kyorin in-licenses Bayer’s phase II sleep apnea drug for €85M+

Dec. 17, 2024

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial milestones.

BioWorld BioWorld Asia Deals and M&A Respiratory Small molecule Asia-Pacific Japan U.S.

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 14, 2025.

Scientific figure illustrating astrocytes and neuron synapse

Glia 2025: Microglial crosstalk could be early Alzheimer’s targeting opportunity

BioWorld

“Loss of synapses and dysfunctional synapses in a region-specific way is important in Alzheimer’s. It’s actually the strongest correlate of cognitive decline, far...

New oral BRD4 inhibitor blocks pathogenic expansion of epithelial progenitors in IPF models

BioWorld Science

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. IPF is thought to result from repeated microinjuries...

BD’s biosciences & diagnostics unit in $17.5B merger with Waters

BioWorld MedTech

Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...